Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study

被引:58
|
作者
Ehmann, Lisa [1 ,2 ]
Zoller, Michael [3 ]
Minichmayr, Iris K. [1 ,2 ]
Scharf, Christina [3 ]
Maier, Barbara [4 ]
Schmitt, Maximilian V. [5 ]
Hartung, Niklas [1 ,6 ]
Huisinga, Wilhelm [6 ]
Vogeser, Michael [4 ]
Frey, Lorenz [3 ]
Zander, Johannes [4 ]
Kloft, Charlotte [1 ]
机构
[1] Free Univ Berlin, Inst Pharm, Dept Clin Pharm & Biochem, Kelchstr 31, D-12169 Berlin, Germany
[2] PharMetrX, Grad Res Training Program, Berlin, Germany
[3] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Anesthesiol, Munich, Germany
[4] Ludwig Maximilians Univ Munchen, Univ Hosp, Inst Lab Med, Munich, Germany
[5] Heidelberg Univ, Inst Pharm & Mol Biotechnol, Heidelberg, Germany
[6] Univ Potsdam, Inst Math, Potsdam, Germany
来源
CRITICAL CARE | 2017年 / 21卷
关键词
beta-Lactam; Intensive care; Pharmacokinetics/Pharmacodynamics; Target attainment; Renal function; Risk assessment tool; Continuous renal replacement therapy; RANDOMIZED CONTROLLED-TRIAL; POPULATION PHARMACOKINETICS; SEVERE SEPSIS; CONTINUOUS-INFUSION; REPLACEMENT THERAPY; INTERMITTENT BOLUS; SEPTIC SHOCK; MULTICENTER; PHARMACODYNAMICS; REQUIREMENTS;
D O I
10.1186/s13054-017-1829-4
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Severe bacterial infections remain a major challenge in intensive care units because of their high prevalence and mortality. Adequate antibiotic exposure has been associated with clinical success in critically ill patients. The objective of this study was to investigate the target attainment of standard meropenem dosing in a heterogeneous critically ill population, to quantify the impact of the full renal function spectrum on meropenem exposure and target attainment, and ultimately to translate the findings into a tool for practical application. Methods: A prospective observational single-centre study was performed with critically ill patients with severe infections receiving standard dosing of meropenem. Serial blood samples were drawn over 4 study days to determine meropenem serum concentrations. Renal function was assessed by creatinine clearance according to the Cockcroft and Gault equation (CLCRCG). Variability in meropenem serum concentrations was quantified at the middle and end of each monitored dosing interval. The attainment of two pharmacokinetic/pharmacodynamic targets (100% T->MIC, 50% T->4xMIC) was evaluated for minimum inhibitory concentration (MIC) values of 2 mg/L and 8 mg/L and standard meropenem dosing (1000 mg, 30-minute infusion, every 8 h). Furthermore, we assessed the impact of CLCRCG on meropenem concentrations and target attainment and developed a tool for risk assessment of target non-attainment. Results: Large inter-and intra-patient variability in meropenem concentrations was observed in the critically ill population (n = 48). Attainment of the target 100% T->MIC was merely 48.4% and 20.6%, given MIC values of 2 mg/L and 8 mg/L, respectively, and similar for the target 50% T->4xMIC. A hyperbolic relationship between CLCRCG (25-255 ml/minute) and meropenem serum concentrations at the end of the dosing interval (C-8h) was derived. For infections with pathogens of MIC 2 mg/L, mild renal impairment up to augmented renal function was identified as a risk factor for target non-attainment (for MIC 8 mg/L, additionally, moderate renal impairment). Conclusions: The investigated standard meropenem dosing regimen appeared to result in insufficient meropenem exposure in a considerable fraction of critically ill patients. An easy-and free-to-use tool (the MeroRisk Calculator) for assessing the risk of target non-attainment for a given renal function and MIC value was developed.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study
    Lisa Ehmann
    Michael Zoller
    Iris K. Minichmayr
    Christina Scharf
    Barbara Maier
    Maximilian V. Schmitt
    Niklas Hartung
    Wilhelm Huisinga
    Michael Vogeser
    Lorenz Frey
    Johannes Zander
    Charlotte Kloft
    Critical Care, 21
  • [2] Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients
    De Waele, Jan J.
    Lipman, J.
    Akova, M.
    Bassetti, M.
    Dimopoulos, G.
    Kaukonen, M.
    Koulenti, D.
    Martin, C.
    Montravers, P.
    Rello, J.
    Rhodes, A.
    Udy, A. A.
    Starr, T.
    Wallis, S. C.
    Roberts, J. A.
    INTENSIVE CARE MEDICINE, 2014, 40 (09) : 1340 - 1351
  • [3] Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study
    Dhaese, Sofie A. M.
    Thooft, Alexander D. J.
    Farkas, Andras
    Lipman, Jeffrey
    Verstraete, Alain G.
    Stove, Veronique
    Roberts, Jason A.
    De Waele, Jan J.
    JOURNAL OF CRITICAL CARE, 2019, 52 : 75 - 79
  • [4] Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study
    Zoller, Michael
    Maier, Barbara
    Hornuss, Cyrill
    Neugebauer, Christina
    Doebbeler, Gundula
    Nagel, Dorothea
    Holdt, Lesca Miriam
    Bruegel, Mathias
    Weig, Thomas
    Grabein, Beatrice
    Frey, Lorenz
    Teupser, Daniel
    Vogeser, Michael
    Zander, Johannes
    CRITICAL CARE, 2014, 18 (04)
  • [5] Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study
    Michael Zoller
    Barbara Maier
    Cyrill Hornuss
    Christina Neugebauer
    Gundula Döbbeler
    Dorothea Nagel
    Lesca Miriam Holdt
    Mathias Bruegel
    Thomas Weig
    Béatrice Grabein
    Lorenz Frey
    Daniel Teupser
    Michael Vogeser
    Johannes Zander
    Critical Care, 18
  • [6] Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients
    Jan J. De Waele
    J. Lipman
    M. Akova
    M. Bassetti
    G. Dimopoulos
    M. Kaukonen
    D. Koulenti
    C. Martin
    P. Montravers
    J. Rello
    A. Rhodes
    A. A. Udy
    T. Starr
    S. C. Wallis
    J. A. Roberts
    Intensive Care Medicine, 2014, 40 : 1340 - 1351
  • [7] Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function
    Gijsen, Matthias
    Elkayal, Omar
    Annaert, Pieter
    Van Daele, Ruth
    Meersseman, Philippe
    Debaveye, Yves
    Wauters, Joost
    Dreesen, Erwin
    Spriet, Isabel
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 53 - 62
  • [8] Therapeutic drug monitoring of meropenem and pharmacokinetic-pharmacodynamic target assessment in critically ill pediatric patients from a prospective observational study
    Maimongkol, Passara
    Yonwises, Wanlika
    Anugulruengkitt, Suvaporn
    Sophonphan, Jiratchaya
    Treyaprasert, Wanchai
    Wacharachaisurapol, Noppadol
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 120 : 96 - 102
  • [9] Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial
    Onichimowski, Dariusz
    Bedzkowska, Anita
    Ziolkowski, Hubert
    Jaroszewski, Jerzy
    Borys, Michal
    Czuczwar, Miroslaw
    Wiczling, Pawel
    PHARMACOLOGICAL REPORTS, 2020, 72 (03) : 719 - 729
  • [10] Meropenem pharmacokinetic/pharmacodynamic target attainment and clinical response in ICU patients: A prospective observational study
    Helset, Elin
    Cheng, Vesa
    Sporsem, Hilde
    Thorstensen, Christian
    Nordoy, Ingvild
    Gammelsrud, Karianne Wiger
    Hanssen, Gorm
    Ponzi, Erica
    Lipman, Jeffrey
    von Der Lippe, Elisabeth
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2024, 68 (04) : 502 - 511